Eton Pharmaceuticals, Inc. (ETON)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q3 '21: 775K Q4 '21: 6.1M Q1 '22: 2.2M Q2 '22: 7.4M Q3 '22: 3.2M Q4 '22: 8.5M Q1 '23: 5.3M Q2 '23: 12M Q3 '23: 7M Q4 '23: 7.3M Q1 '24: 8M Q2 '24: 9.1M Q3 '24: 10.3M Q4 '24: 11.6M Q1 '25: 17.3M Q2 '25: 18.9M Q3 '25: 22.5M Q4 '25: 21.3M Q1 '26: 24.3M Q2 '26: 37.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 9M 18M 27M Q3 '21: 121K Q4 '21: 5.7M Q1 '22: 1.3M Q2 '22: 4.6M Q3 '22: 2M Q4 '22: 6.4M Q1 '23: 3.3M Q2 '23: 9.7M Q3 '23: 4.4M Q4 '23: 3.6M Q1 '24: 5M Q2 '24: 5.6M Q3 '24: 6.3M Q4 '24: 6.5M Q1 '25: 9.9M Q2 '25: 11.9M Q3 '25: 7.9M Q4 '25: 13.1M Q1 '26: 14.7M Q2 '26: 25.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-10M -5M 0 5M 10M 15M Q3 '21: -5.8M Q4 '21: 1.3M Q1 '22: -5.1M Q2 '22: -1.3M Q3 '22: -2.9M Q4 '22: 1.1M Q1 '23: -2.5M Q2 '23: 3.9M Q3 '23: -548K Q4 '23: -2M Q1 '24: -800K Q2 '24: -2.9M Q3 '24: 509K Q4 '24: 629K Q1 '25: -470K Q2 '25: -1.5M Q3 '25: -1.4M Q4 '25: 2.5M Q1 '26: 2.4M Q2 '26: 12.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-8M -4M 0 4M 8M 12M Q3 '21: -6.1M Q4 '21: 1M Q1 '22: -5.3M Q2 '22: -1.6M Q3 '22: -3M Q4 '22: 912K Q1 '23: -2.7M Q2 '23: 4.6M Q3 '23: -579K Q4 '23: -2.3M Q1 '24: -811K Q2 '24: -3M Q3 '24: 627K Q4 '24: -598K Q1 '25: -1.6M Q2 '25: -2.6M Q3 '25: -1.9M Q4 '25: 1.5M Q1 '26: 1.6M Q2 '26: 11.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 5M 10M 15M Q3 '21: 654K Q4 '21: 372K Q1 '22: 849K Q2 '22: 2.7M Q3 '22: 1.2M Q4 '22: 2.1M Q1 '23: 2M Q2 '23: 2.3M Q3 '23: 2.6M Q4 '23: 3.7M Q1 '24: 3M Q2 '24: 3.4M Q3 '24: 4M Q4 '24: 5.2M Q1 '25: 7.4M Q2 '25: 7M Q3 '25: 14.6M Q4 '25: 8.2M Q1 '26: 9.5M Q2 '26: 12.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-10M -5M 0 5M 10M 15M Q2 '21: -369K Q3 '21: -3M Q4 '21: -5.1M Q1 '22: 1.2M Q2 '22: 2.5M Q3 '22: -1.7M Q4 '22: 2.8M Q1 '23: -1.5M Q2 '23: 7.1M Q3 '23: 873K Q4 '23: 387K Q1 '24: -2.5M Q2 '24: 1.3M Q3 '24: 3M Q4 '24: -765K Q1 '25: 2.1M Q2 '25: 8M Q3 '25: 12M Q1 '26: 7.4M Q2 '26: 7.3M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-8M -4M 0 4M 8M 12M Q4 '20: -7.2M Q3 '21: -3M Q4 '21: -5.1M Q1 '22: 1.2M Q2 '22: 2.5M Q3 '22: -1.7M Q4 '22: 2.8M Q1 '23: -1.5M Q2 '23: 7.1M Q3 '23: 873K Q4 '23: 387K Q1 '24: -2.5M Q2 '24: 1.3M Q3 '24: 3M Q4 '24: -777K Q1 '25: 2.1M Q2 '25: 8M Q3 '25: 11.7M Q1 '26: 7.3M Q2 '26: 7.2M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 18.1M Q2 '20: 21M Q1 '21: 26.5M Q2 '21: 25.2K Q3 '21: 25.3M Q1 '22: 25.3M Q2 '22: 25.1M Q3 '22: 25.4M Q1 '23: 25.5K Q2 '23: 26K Q3 '23: 25.7K Q1 '24: 25.8K Q2 '24: 25.8K Q3 '24: 26.6M Q1 '25: 26.9M Q2 '25: 26.9M Q3 '25: 26.9M Q1 '26: 31.5M Q2 '26: 32.8M Q1 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q2 '18: -3.65 Q3 '18: -3.30 Q4 '18: -4.73 Q1 '19: -4.10 Q2 '19: -3.49 Q3 '19: -3.12 Q4 '19: -1.03 Q1 '20: -1.11 Q2 '20: -1.16 Q3 '20: -1.19 Q4 '20: -1.36 Q1 '21: -0.67 Q2 '22: -0.46 Q3 '22: -0.34 Q4 '22: -0.36 Q2 '25: -0.17 Q3 '25: -0.26 Q4 '25: -0.17 Q1 '26: -0.06 Q2 '26: 0.39 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '22 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.